XY Inc. v. Trans Ova Genetics: 7-Patent Sperm Sorting Dispute Dismissed With Prejudice
XY, Inc. and co-plaintiffs Inguran LLC and Beckman Coulter sued Trans Ova Genetics over seven patents covering MoFlo SX sperm sorting technology. After 3,153 days — nearly nine years — in the Colorado District Court, all claims and counterclaims were dismissed with prejudice under a joint stipulation, each party bearing its own costs.
Nine years, seven patents, and a stipulated end to a hard-fought sperm sorting dispute
Filed in April 2017 in the U.S. District Court for Colorado, this case pitted XY, Inc. — joined by Inguran LLC d/b/a ST Genetics and Beckman Coulter, Inc. — against Trans Ova Genetics, LC, one of the largest bovine reproductive services providers in North America. The plaintiffs asserted seven U.S. patents spanning core sperm sorting, flow cytometry, and cell separation technologies, all embodied in the MoFlo SX sperm sorter platform.
The case closed on 5 December 2025 via a Fed. R. Civ. P. 41(a) stipulated dismissal with prejudice. Critically, both sides agreed that all claims and counterclaims — including any counterclaims Trans Ova may have asserted — were extinguished in their entirety, with each party absorbing its own legal costs. A with-prejudice dismissal bars the plaintiffs from re-filing any of the same patent claims against Trans Ova in a new action.
A case spanning nearly 3,153 days suggests the parties exhausted significant procedural and substantive litigation before reaching resolution. The mutual cost-bearing arrangement and simultaneous extinguishment of counterclaims are consistent with a negotiated commercial settlement, though the public record does not disclose any licensing terms, royalty arrangements, or business agreements that may underpin the stipulation. The precise trigger — whether a licensing deal, market exit, or strategic compromise — remains undisclosed.
Filing to Dismissed with Prejudice in 3153 days
3,153 days — nearly 9 years in litigation, well above the median complex patent case duration
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a) stipulated dismissal: a negotiated, permanent exit
A Fed. R. Civ. P. 41(a) dismissal with prejudice is a consensual termination requiring both parties’ agreement. Unlike a judgment on the merits, no court finding of infringement or invalidity is made. However, the with-prejudice designation carries legal finality — the plaintiffs are barred from reasserting the same claims against Trans Ova in any subsequent action. Courts treat it as a final judgment for res judicata purposes.
Permanent bar on re-filingXY and co-plaintiffs close the action but retain the patents
While XY, Inguran, and Beckman Coulter cannot re-assert these seven patents against Trans Ova, they retain full ownership and enforceability of the patents against third parties. The with-prejudice dismissal forecloses only this defendant. If a confidential licence or commercial agreement underlies the settlement, the plaintiffs may have secured ongoing value without a court order — though this is not confirmed by the public record.
Patents remain enforceable vs. othersTrans Ova avoids an infringement finding — and extinguishes its own counterclaims
Trans Ova exits without any judicial finding of infringement, preserving its commercial reputation and avoiding an injunction or damages award. Notably, its counterclaims — which may have included invalidity challenges — were also dismissed with prejudice. This means Trans Ova cannot revive those invalidity arguments in a future action against XY on these same patents, a significant concession that suggests a balanced commercial resolution.
No infringement finding; counterclaims extinguishedSeven sperm sorting patents survive intact — risk remains for other market players
Because no court adjudicated the validity or scope of XY’s seven patents, all seven remain presumptively valid and enforceable. Competitors in bovine reproductive services and flow cytometry-based cell sorting who use similar MoFlo SX-type technology should treat this outcome as a non-event for invalidity purposes. XY’s patent portfolio may now be deployed against other operators, and the 3,153-day litigation history signals the plaintiffs’ willingness to sustain prolonged enforcement campaigns.
Portfolio enforcement risk remains liveFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | XY, Inc. | Company | Agricultural biotech and sperm sorting IP licensor — holder of US9145590B2 and 6 further patentsSearch in Eureka ↗ |
| Defendant | Trans Ova Genetics, LC | Individual | Trans Ova Genetics, LC — major U.S. bovine reproductive services and embryo transfer companySearch in Eureka ↗ |
| Plaintiff counsel | Clark T. Gordon | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Clayton N. Matheson | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel Lynn Moffett | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff counsel | George Andrew Lever Rosbrook | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kirt Stephen O’Neill | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rehan M. Safiullah | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Thomas Watson Landers , IV | Attorney | Counsel for XY, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Akin Gump Strauss Hauer & Feld LLP | Law Firm | Representing XY, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Fabricant LLP | Law Firm | Representing XY, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian L. Saunders | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Charles D. Ossola , Sr. | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | David A. Kelly | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Deborah Pollack-Milgate | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Donald E. Lake , III | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Douglas McCarley Garrou | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | George G. Matava | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Jason M. Beach | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Joshua E. Ney | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Joshua M. Kalb | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Lauren U. Baker | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Mark A. Hagedorn | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Mark C. Nelson | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Roya Rahmanpour | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant counsel | Samantha K. Picans | Attorney | Counsel for Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant law firm | Barnes & Thornburg LLP | Law Firm | Representing Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant law firm | Dickinson Wright PLLC | Law Firm | Representing Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant law firm | Hunton Andrews Kurth LLP | Law Firm | Representing Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant law firm | Lewis Brisbois Bisgaard & Smith LLP | Law Firm | Representing Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant law firm | Quinn Emanuel Urquhart & Sullivan LLP | Law Firm | Representing Trans Ova Genetics, LCSearch in Eureka ↗ |
| Defendant law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Trans Ova Genetics, LCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Colorado District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation expressly invokes Fed. R. Civ. P. 41(a) and names all three plaintiffs — XY LLC, Inguran LLC, and Beckman Coulter — alongside Trans Ova, ensuring no party can later dispute the scope of the dismissal. The with-prejudice designation and explicit reference to ‘all claims and counterclaims in their entirety’ leaves no residual live issue between these parties on these patents. The each-party-bears-own-costs clause removes any financial leverage either side might otherwise hold post-dismissal, reinforcing the interpretation of a commercially negotiated resolution rather than a unilateral concession.
US9145590B2 and six further patents — MoFlo SX sperm sorting and flow cytometry platform
The seven asserted patents collectively protect the core intellectual infrastructure of flow cytometry-based sperm sorting — the technology that enables sex-selection of bovine semen for commercial livestock breeding. Application dates span from late 1999 (US6372422B1) through 2013 (US9365822B2), reflecting a sustained patenting programme across successive generations of the MoFlo SX platform. The portfolio includes a reissue patent (USRE046559E), suggesting XY pursued claim broadening or correction to extend protection. Together, the patents cover cell staining, sorting apparatus, DNA content discrimination, and high-speed recovery methods.
For the bovine reproductive services sector, this portfolio represents a significant gatekeeping position. XY and Inguran (ST Genetics) collectively control a substantial share of sexed semen technology IP globally. Any competitor offering flow cytometry-based sperm sorting — whether for bovine, equine, or other livestock applications — must navigate this multi-layered portfolio. The inclusion of Beckman Coulter as a co-plaintiff signals that instrument manufacturers are also drawn into enforcement actions, raising the risk profile for equipment suppliers as well as service operators.
Should you run an FTO analysis against XY’s sperm sorting patent portfolio?
If your organisation designs, manufactures, or commercially operates flow cytometry-based sperm sorting instruments — including MoFlo-type platforms or analogous cell separation systems for livestock reproduction — this portfolio demands serious FTO attention. The seven patents span core apparatus, methods, and consumables, and XY has demonstrated willingness to litigate for nearly a decade. Bovine reproductive service providers, veterinary biotech developers, and OEM instrument suppliers are all within the enforcement perimeter suggested by this case.
PatSnap Eureka’s FTO Search Agent can map each of the seven asserted patents against your specific product claims, flag active claim scope post any reexamination or reissue proceedings, and identify prior art that may have survived this litigation. Eureka also monitors for new continuations or divisionals filed by XY and Inguran, so your FTO remains current as the portfolio evolves. Start with a claim chart comparison across US9145590B2, US6372422B1, and USRE046559E — the foundational and reissue patents most likely to carry the broadest claim scope.
Run a freedom-to-operate analysis on US9145590B2 to assess your product’s exposure
Run FTO in Eureka →Similar sperm sorting and flow cytometry patent cases in U.S. district courts
Cases involving flow cytometry, sexed semen technology, and reproductive biotech IP in U.S. district courts — most relevant to XY v. Trans Ova practitioners.
What this case signals for the animal reproductive biotech IP landscape
Nine years of litigation over sperm sorting IP reveals a fiercely contested technology space where patent portfolios carry durable commercial leverage.
Prolonged litigation without adjudication preserves plaintiff enforcement options
With no invalidity ruling on record, XY’s seven-patent portfolio exits this case fully intact. Companies operating in flow cytometry-based reproductive technology should not interpret this dismissal as a cleared path — the patents remain presumptively valid and have already survived nearly a decade of adversarial scrutiny.
Mutual cost-bearing and counterclaim extinction signal a balanced commercial deal
When both parties agree to bear their own costs and simultaneously dismiss all counterclaims with prejudice, it typically signals a negotiated resolution rather than a capitulation by either side. Competitors and investors should note that Trans Ova’s potential invalidity arguments were also extinguished — suggesting the parties reached a commercially stable equilibrium.
XY v Trans — key questions answered
A dismissal with prejudice under Fed. R. Civ. P. 41(a) permanently bars XY, Inguran, and Beckman Coulter from re-asserting the same patent claims against Trans Ova in a new action. No court ruling on infringement or invalidity was made. Trans Ova’s counterclaims were also dismissed with prejudice, extinguishing any invalidity arguments it might otherwise revive.
XY and co-plaintiffs asserted seven U.S. patents: US9145590B2, US8652769B2, US9365822B2, USRE046559E, US6372422B1, US7208265B1, and US7723116B2. These cover sperm sorting methods, flow cytometry apparatus, cell staining and separation, and high-speed sperm recovery — all central to the MoFlo SX sperm sorter platform.
The case involved seven patents across a technically complex biotechnology domain, three co-plaintiffs, and a defendant that mounted counterclaims — likely including invalidity challenges. Complex patent cases in district courts frequently involve extended claim construction proceedings, inter partes review interactions at the USPTO, and extensive fact and expert discovery. The 3,153-day duration is consistent with this level of complexity, though specific procedural events are not fully disclosed in the public record.
No. A stipulated dismissal with prejudice carries no adjudication of patent validity. All seven asserted patents exit the case with their presumption of validity intact. Trans Ova’s own invalidity counterclaims were also dismissed with prejudice, meaning it cannot revive those challenges, but this has no binding effect on third parties who remain free to challenge the patents independently.
Beckman Coulter’s inclusion as a co-plaintiff alongside XY and Inguran suggests that the MoFlo SX instrument manufacturer held relevant patent rights or licensing interests sufficient to confer standing. This is commercially significant for the sector because it signals that instrument OEMs — not just service operators — may be drawn into sperm sorting patent enforcement actions, raising the risk profile for equipment manufacturers and their commercial partners.
PatSnap Eureka searches patents and litigation data to answer instantly.